Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBITDA (2020 - 2025)

Historic EBITDA for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$23.5 million.

  • Janux Therapeutics' EBITDA fell 2625.19% to -$23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.2 million, marking a year-over-year decrease of 10408.31%. This contributed to the annual value of -$67.5 million for FY2024, which is 2032.87% down from last year.
  • Latest data reveals that Janux Therapeutics reported EBITDA of -$23.5 million as of Q3 2025, which was down 2625.19% from -$33.9 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' EBITDA peaked at -$2.3 million during Q1 2021, and registered a low of -$33.9 million during Q2 2025.
  • Over the past 5 years, Janux Therapeutics' median EBITDA value was -$15.9 million (recorded in 2024), while the average stood at -$15.8 million.
  • As far as peak fluctuations go, Janux Therapeutics' EBITDA crashed by 75660.83% in 2021, and later soared by 6045.21% in 2024.
  • Over the past 5 years, Janux Therapeutics' EBITDA (Quarter) stood at -$13.7 million in 2021, then decreased by 11.77% to -$15.3 million in 2022, then surged by 35.27% to -$9.9 million in 2023, then tumbled by 160.98% to -$25.9 million in 2024, then increased by 9.22% to -$23.5 million in 2025.
  • Its EBITDA was -$23.5 million in Q3 2025, compared to -$33.9 million in Q2 2025 and -$21.9 million in Q1 2025.